Kiniksa Pharmaceuticals, Ltd. provided revenue guidance for the year 2024. For the period, the company expects net revenue to be between $360 million and $380 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.53 USD | -3.27% | -2.74% | +11.35% |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
04-23 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.35% | 1.39B | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.09% | 22.25B | |
-13.14% | 22.09B | |
-7.82% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Revenue Guidance for the Year 2024